Treatment of brain metastases in patients with melanoma

The Lancet Oncology

Volumn 13, Issue 5, 2012, Pages 434-435

  Fisher, Rosalie ^a   Larkin, James ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; IPILIMUMAB; TEMOZOLOMIDE; VEMURAFENIB;

ADVANCED CANCER; BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COLITIS; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG PENETRATION; DRUG SAFETY; HUMAN; LETTER; MELANOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; HUMANS; MALE; MELANOMA; SKIN NEOPLASMS;

EID: 84860495477     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70118-3     Document Type: Letter

References (9)

1. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012, published online March 27. 10.1016/S1470-2045(12)70090-6.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
3. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
4. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
5. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. Proc Am Soc Clin Oncol 2010, 28(suppl):8503. (abstr).
6. Dummer R, Goldinger SM, Wagner I, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. Proc Am Soc Clin Oncol 2011, 29(suppl):8548. (abstr).
7. Rochet NM, Kottschade LA, Markovic SN Vemurafenib for melanoma metastases to the brain. N Engl J Med 2011, 365:2439-2441.
8. Weber JS, Amin A, Minor D, Siegel J, Berman D, O'Day SJ Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 2011, 21:530-534.
9. Shapiro DG, Samlowski WE Management of melanoma brain metastases in the era of targeted therapy. J Skin Cancer 2011, 845863.